Journal Article

FZJ-2019-02818

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis

Schweitzer, F. ; Laurent, S. ; Fink, G. R.FZJ* ; Barnett, M. H. ; Reddel, S. ; Hartung, H.-P. ; Warnke, C. (Corresponding author)

2019
Ovid [S.l.]

This record in other databases:      

Please use a persistent id in citations: doi:10.1097/WCO.0000000000000701

Abstract: A variety of high-efficacy disease-modifying therapies (DMTs) are available for the treatment of multiple sclerosis (MS). After evaluation and approval by regulatory agencies, DMTs are likely to be administered to patients whose characteristics differ from those enrolled in clinical trials. This may contribute to the emergence of unexpected adverse events observed in the real-world setting. Higher age may be a relevant factor that could change the benefit–risk balance of DMTs, as it may associate with lower efficiency and higher frequency of adverse events.

---

Contributing Institute(s):

1. Kognitive Neurowissenschaften (INM-3)

Research Program(s):

1. 572 - (Dys-)function and Plasticity (POF3-572) (POF3-572)

Appears in the scientific report 2019

---

Database coverage:
; Allianz-Lizenz ; BIOSIS Previews ; BIOSIS Reviews Reports And Meetings ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---